Cradles to Crayons Massachusetts’ Post

Did you know that clinical trials provide a viable healthcare solution? Learn more about why you should participate.

The PPMD Town Hall on Clinical Trials is underway TODAY, March 4th, during PPMD's 2024 Advocacy Conference in Washington, D.C.! This meeting is a platform for families impacted by Duchenne and Becker to share their experiences and insights on past, present, and future clinical trials. The primary goal is to hear directly from families and gather valuable input to shape PPMD's advocacy efforts, especially in interactions with the FDA on drug development.  AGENDA HIGHLIGHTS: - Parent/Patient Panel: Diverse voices at different ages and stages sharing their clinical trial experiences, discussing challenges, and expressing hopes for outcomes. - Professional Panel on Patient Preference and Clinical Trials: Featuring a representative from FDA CDER and clinicians covering FDA updates, issues in clinical trials, and potential solutions.  Following the meeting, a recap will be shared with the community and learnings will be integrated into PPMD's advocacy strategy moving forward as we interact with federal agencies (including FDA, NIH, DOD, and CDC). Together, we're working to enhance the clinical trial landscape for Duchenne and Becker families and contribute to policy strategies for improved outcomes. #PPMDAdvocacy

For generations, Black women have not been equally included in necessary health research, resulting in a lack of information specific to Black women’s health. Now is the time to include Black women in research as we step toward improving cancer outcomes and eliminating disparities. By joining together, we can gain valuable insights into Black women's diverse experiences and health challenges and learn how to deliver culturally competent and effective interventions, treatments, and preventive measures. Here is another take on "The Importance of Diversity in Clinical Trials": https://lnkd.in/eMpzpStY We have to be a part of the change that we want to see in healthcare. After you watch - please consider joining us at VOICES.CANCER.ORG! #ACS #VOICES #100kstrong

An interesting development this week! This is right at the intersection of an organisation's purpose, its legacy, and a new data-informed process! JDRF, the leading type 1 diabetes (T1D) research and advocacy organization, announced its new name: Breakthrough T1D The group stated its new name was selected following a rigorous, data-informed process because it more accurately conveys the non-profit’s ability to connect with and work on behalf of the entire type 1 diabetes community! JDRF is an amazing organisation and does fantastic work. But... could changing JDRF's name to Breakthrough T1D jeopardise the established brand recognition and emotional connection the organisation has built over the years? Significant resources required for rebranding? Change ≠ easy Juvenile Diabetes is no longer a clinically used term. 88% of people living with type 1 diabetes are adults. And our language matters. But did the name JDRF come in the way of its purpose? This is one to watch!

Diversity, Equity and Inclusion (DEI) is a critical part of any business, regardless of size, and most especially in our industry in life sciences. I couldn't put it better than Ben Osborn - "If we don't understand the really diverse needs of patients how can we develop the innovative medicines that they ultimately rely on." Knowing we need to do it is one thing, what I like about this episode of Cut the Chat is that Ben Osborn and Sabine Hutchison discuss simple practical steps smaller organizations can take to be closer to DEI. Happy listening! #Cutthechatpodcast #DEI #Diversityandinclusion #LifeScienceInsider https://lnkd.in/eu2wJi_w

In this article by Healthcare Business Today, Robert Church and Stephanie Agu discuss the importance of diversity and inclusion in clinical trials. Read the full article here: https://lnkd.in/e3AzqCMc #diversity #inclusion #clinicaltrials

I don't think I truly understood what diversity, equity and inclusion meant until I joined Merck/MSD. Everyone has a different perspective, different experiences and ALL are equally important! We need more of these perspectives. If you're interested in clinical careers in pharma - check out the below post and register for this upcoming event!

Is your clinical trial diverse? Increasing diversity in clinical research has been the main goal across the industry. But the question is, is diversity progressing? After the FDA passed the FDORA, many organizations have adopted strategies that help track their progress of diversifying their clinical trials. The Clinical Trials Transformation Initiative focuses on implementing diversity and inclusion practices to promote change in the overall design. By using the Diversity Maturity Model, organizations can physically see their efforts and can adjust accordingly. If your clinical trials continue to lack diversity, we encourage you to review the Diversity Maturity Model for Organizational-Level Strategies. The new year is approaching, let’s plan on making this next year more inclusive! Check out the following article to learn more about the Diversity Maturity Model: https://lnkd.in/g8idjPKm. #Diversity #Inclusion #Collaboration #Education #Engagement #FDORA #CTTI #MeasuringProgress #DiversityProgression #ClinicalTrials #DCT #PioneeringRepresentationInDiscovery #Reveles

As we conclude another year, we are proud to share the National Association for Proton Therapy's 2023 Advocacy Report, brimming with noteworthy insights and achievements deserving of celebration! Throughout 2023, NAPT has redoubled its commitment to raising awareness and garnering support for proton therapy, and we are eager to share the substantial progress made on behalf of the proton industry: 1️⃣ NAPT has firmly established itself as a prominent voice in healthcare policy, passionately advocating for equitable access to proton beam therapy (PBT) and diligently addressing prior authorization challenges. 2️⃣ We have hosted numerous stakeholder events, engaged with bipartisan representatives, and fostered connections with the White House Cancer Moonshot initiative, all aimed at underscoring the critical importance of PBT. 3️⃣ Our advocacy extended to ensuring veterans' access to PBT through the Department of Veterans Affairs, with a strong emphasis on highlighting the inherent value of this groundbreaking treatment. 4️⃣ We supported our members' active involvement in grassroots advocacy, providing invaluable firsthand insights into the benefits of proton therapy. 5️⃣ NAPT's unwavering dedication to addressing prior authorization barriers is exemplified by our active participation in essential healthcare coalitions. Looking ahead to 2024, NAPT remains steadfast in its mission to advocate for patient access to PBT. Read the full report or download a copy here: https://lnkd.in/gqJNfYMa

In 2010, after winning the Henry McCance Award at the Yale School of Management, Alea Diagnostics participated in the PepsiCo Refresh project hoping to raise early funds to start the company. The early intervention statistics cited in the video are unchanged over a decade later - and have been unchanged for over 40 years. The end of the video was dedicated to all the children waiting to be found. So many children it turns out. ---- 1.3 million children with autism were born in the US between 2010 and 2023. It is estimated that only 39,000 (3%) have received early intervention. The economic impact of failures to identify and treat early for this small cohort is $4.2T. The human costs cannot be quantified. The Alea Diagnostics kids featured in the animation are based on the founder Linda Craib, MBA and her grandson, both age 3. Go to AleaDx.com to learn more about how we help business and society. Or visit Lorestry.com to learn more about how we help parents tell their child's story. #infantmentalhealth #earlyintervention #autism #childdevelopment #AleaDx #developmentmonitoring https://lnkd.in/e-QengJi